Kinase inactivation of GSK-3β, such as by the GSK-3β inhibitor AR79, promotes prostate cancer growth and mammary tumorigenesis by activating the canonical Wnt pathway [30, 31]. This evidence concerns the gene GSK3B and prostate carcinoma.